<DOC>
	<DOCNO>NCT00975637</DOCNO>
	<brief_summary>The study evaluate efficacy AMG 827 compare placebo measure percent improvement PASI score week 12 .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Efficacy AMG 827 Subjects With Psoriasis</brief_title>
	<detailed_description>The study evaluate efficacy AMG 827 compare placebo measure percent improvement PASI score week 12 . Subjects randomize ina 1:1:1:1:1 ratio . Subjects randomize receive AMG 827 receive 70 , 140 , 210 mg day 1 week 4 8 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject stable moderate severe plaque psoriasis least 6 month Subject receive least one previous phototherapy systemic psoriasis therapy candidate receive phototherapy systemic psoriasis therapy opinion investigator . Subject involved BSA ≥ 10 % PASI ≥ 12 screen baseline . Subject diagnose erythrodermic psoriasis , pustular psoriasis , medicationinduced , medicationexacerbated psoriasis . Evidence skin condition time screen visit ( eg , eczema , guttate psoriasis ) would interfere evaluation effect IP psoriasis . Subject active CTCAE grade 2 high infection Subject significant concurrent medical condition laboratory abnormality , define study protocol . Subject use follow therapy within 14 day first dose : UVB therapy topical psoriasis therapy Class I II topical steroid Subject use follow therapy within 28 day first dose : Class I II topical steroid , UVA therapy ( without psoralen ) , systemic psoriasis therapy Subject use follow therapy within 3 month first dose : adalimumab , alefacept , etanercept , infliximab , certolizumab , live vaccine Subject use antiIL12/IL23 inhibitor within 6 month first dose Subject previously use antiIL17 biologic therapy , efalizumab , rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>